Siemens Healthineers proposes Peer Schatz to Annual Shareholders' Meeting as new Supervisory Board member

• Extension of the Supervisory Board expertise will cover the company’s portfolio in an ideal way
• Peer Schatz is an outstanding expert in laboratory diagnostics, precision medicine and digitalization with an international background
• Proposed term of five years

The Supervisory Board of Siemens Healthineers AG is proposing a new Supervisory Board member to the shareholders for election at the Annual Shareholders' Meeting on February 12, 2021: Peer Schatz (55), long-serving CEO of QIAGEN N.V., a leading global provider of complete solutions for gaining molecular insights from biological samples. Schatz, who lived and worked in the U.S. for many years, has more than 30 years of expertise in life sciences, precision medicine and bioinformatics.

If Peer Schatz were elected, the number of Supervisory Board members of Siemens Healthineers AG would increase from currently nine to ten. The Annual Shareholders' Meeting will first have to take a decision on an amendment to the Articles of Association, which allows a higher number of members on the Supervisory Board. The election would be for a term of five years.

"With Peer Schatz, an outstanding entrepreneur and one of the most internationally renowned and recognized diagnostic experts is up for election. His many years of extensive experience will be an excellent addition to the expertise of the Supervisory Board, especially with regard to the important areas of diagnostics and digitalization. With the nomination, we also reflect the increased demands on the company by its growing internationality," explains Prof. Dr. Ralf P. Thomas, Chairman of the Supervisory Board of Siemens Healthineers AG.

At the beginning of his professional career, Peer Schatz held various positions at Sandoz AG and Computerland, and was involved in creating various start-up companies in Europe and the USA. In 1993, he joined QIAGEN – at a time when the company had about 30 employees and revenue of USD 2 million. Under his leadership, QIAGEN grew into a global company with more than 5,100 employees and annual revenues of more than USD 1.5 billion. Peer Schatz is currently Managing Director of PS Capital Management GmbH as well as Chairman of the Supervisory Board of Centogene N.V. and co-founder and Chairman of the Board of Resolve Biosciences GmbH.

Peer Schatz was a founding member of the “Deutsche Corporate Governance Kommission” in Germany that developed the first corporate governance framework that is still the guiding standard in the country today. He was also co-chair of the World Economic Forum's Precision Medicine Council from 2016 to 2020. Peer Schatz is of Austrian and Swiss nationality. He studied at the University of St. Gallen in Switzerland, where he received a master's degree in 1989. In 1991, he earned a Master of Business Administration degree from the Graduate School in Business at the University of Chicago.

Link to press picture

Link to Annual Shareholders' Meeting 2021